What is Nurix Therapeutics, Inc.'s gross unrealized gains?

Nurix Therapeutics, Inc. (NRIX) reported gross unrealized gains of $88K in Q4 2025.

Nurix Therapeutics, Inc. NRIX Gross Unrealized Gains

Gross Unrealized Gains at other companies

Viridian Therapeutics, Inc.VRDN

——

Nuvation BioNUVB

——

BridgeBio PharmaBBIO

——

Ionis PharmaceuticalsIONS

——

Nektar TherapeuticsNKTR

——

BioCryst PharmaceuticalsBCRX

——

Other financials

Income statement

See full

Revenue$6.3M-66.1%

Operating income-$92.5M-47.1%

Net income-$87.2M-54.7%

EPS (diluted)-$0.79-17.9%

Balance sheet

See full

Cash & equivalents$72.2M-6.1%

Total debt$58.7M+120%

Total equity$480.9M0.0%

Total assets$636.1M+3.4%

Cash flow

See full

Operating cash flow-$71.9M-17.7%

CapEx$1.0M-70.0%

Free cash flow-$73.0M-13.0%

Valuation

See full

Market cap$2B+40.1%

Profitability

See full

Operating margin-439.3%+35.3pp

Net margin-411.4%+52.7pp

FCF margin-378.7%+24.1pp

Returns & leverage

See full

Return on equity-61.4%-2.5pp

Debt / equity0.1×+0.1×

Current ratio6×-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s gross unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s gross unrealized gains?: Nurix Therapeutics, Inc. (NRIX) reported gross unrealized gains of $88K in Q4 2025.